Non-aqueous solutions [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2020-02-24 09:58 (1128 d 06:00 ago) – Posting: # 21188
Views: 1,069

Good morning fellow BEBACers,

EMA BE guidelines for aqueous oral solutions are straight forward. I would assume that BE studies cannot be waived for oral solutions formulated with non-aqueous carriers (medium chain triglycerides) due to the potential for formulation effects even when formulations are Q1Q2 (my assumption is that it would not be possible to confirm Q2 due to the heterogeneity of the triglyceride chain lengths obtained from different providers). Is this your understanding as well?

Are there any other issues to consider, either from a regulatory or clinical standpoint, due to the non-aqueous carrier and seeking registration? For example, if the RLD is not available in this pharmaceutical form, would a article 10(3) be more appropriate than 10(1)? Thank you in advance.

Complete thread:

UA Flag
Activity
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
19 visitors (0 registered, 19 guests [including 8 identified bots]).
Forum time: 16:58 CEST (Europe/Vienna)

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5